News
SGLT2 inhibitors significantly improve hemoglobin and hematocrit levels in CKD patients, enhancing anemia management. The KDIGO 2024 guideline endorses SGLT2 inhibitors for CKD patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback